Targeting Squalene Epoxidase Confers Metabolic Vulnerability and Overcomes Chemoresistance in HNSCC
Advanced Science · 2023
DOI: 10.1002/advs.202206878 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Xinyuan Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, China. Hauptthemen laut MEDLINE: Squalene Monooxygenase, Head and Neck Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Provincial Science and Technology Project Foundation, Scientific Research Talent Cultivation Project of Stomatological Hospital.
Abstract (Originalsprache)
Cisplatin resistance poses a substantial hurdle in effectively treating head and neck squamous cell carcinoma (HNSCC). Utilizing multiple tumor models and examining an internal HNSCC cohort, squalene epoxidase (SQLE) is pinpointed as a key driver of chemoresistance and tumorigenesis, operating through a cholesterol‐dependent pathway. Comprehensive transcriptomic analysis reveals that SQLE is essential for maintaining c‐Myc transcriptional activity by stabilizing the c‐Myc protein and averting its ubiquitin‐mediated degradation. Mechanistic investigation demonstrates that SQLE inhibition diminishes Akt's binding affinity to lipid rafts via a cholesterol‐dependent process, subsequently deactivating lipid raft‐localized Akt, reducing GSK‐3 β phosphorylation at S9, and increasing c‐Myc phosphorylation at T58, ultimately leading to c‐Myc destabilization. Importantly, employing an Sqle conditional knockout mouse model, SQLE's critical role in HNSCC initiation and progression is established. The preclinical findings demonstrate the potent synergistic effects of combining terbinafine and cisplatin in arresting tumor growth. These discoveries not only provide novel insights into the underlying mechanisms of SQLE‐mediated cisplatin resistance and tumorigenesis in HNSCC but also propose a promising therapeutic avenue for HNSCC patients unresponsive to conventional cisplatin‐based chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, China.
- Department of Dentistry, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
- Department of Stomatology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China.
- Department of Endodontics, Jiangsu Key Laboratory of Oral Diseases, Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, 210029, China.
- Division of Oral Biology and Medicine, School of Dentistry, University of California Los Angeles, Los Angeles, CA, 90095, USA.
ORCID-Profile: Li Cui
Förderung
- National Natural Science Foundation of China
- Guangdong Provincial Science and Technology Project Foundation
- Scientific Research Talent Cultivation Project of Stomatological Hospital
- Southern Medical University
- Science Research Cultivation Program of Stomatological Hospital
Zitieren
APA
Zhao, X., Guo, B., Sun, W., Yu, J., & Cui, L. (2023). Targeting Squalene Epoxidase Confers Metabolic Vulnerability and Overcomes Chemoresistance in HNSCC. Advanced Science. https://doi.org/10.1002/advs.202206878
Vancouver
Zhao X, Guo B, Sun W, Yu J, Cui L. Targeting Squalene Epoxidase Confers Metabolic Vulnerability and Overcomes Chemoresistance in HNSCC. Advanced Science. 2023. doi:10.1002/advs.202206878
BibTeX
@article{Zhao2023,
author = {Zhao, Xinyuan and Guo, Bing and Sun, Wenjuan and Yu, Jinhua and Cui, Li},
title = {Targeting Squalene Epoxidase Confers Metabolic Vulnerability and Overcomes Chemoresistance in HNSCC},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202206878}
}
EUVIMED